利凡斯的明

化合物

利凡斯的明(英語:Rivastigmine,商品名:憶思能,Exelon等)是一種含氮有機化合物,分子式C14H22N2O2,屬於膽鹼酯酶抑制劑,用於治療輕度至中度阿茲海默症[4]

利凡斯的明
臨床資料
商品名英語Drug nomenclatureExelon, Prometax, others
AHFS/Drugs.comMonograph
MedlinePlusa602009
核准狀況
懷孕分級
給藥途徑By mouth, transdermal patch
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度60 to 72%
血漿蛋白結合率40%
藥物代謝Liver, via pseudocholinesterase
生物半衰期1.5 hours
排泄途徑97% in urine
識別資訊
  • (S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate
CAS號123441-03-2  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.120.679 編輯維基數據鏈接
化學資訊
化學式C14H22N2O2
摩爾質量250.34 g·mol−1
3D模型(JSmol英語JSmol
  • O=C(Oc1cc(ccc1)[C@@H](N(C)C)C)N(CC)C
  • InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1 checkY
  • Key:XSVMFMHYUFZWBK-NSHDSACASA-N checkY

參考文獻

編輯
  1. ^ Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [30 March 2024]. 
  2. ^ Product monograph brand safety updates. Health Canada. 7 July 2016 [1 April 2024]. 
  3. ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. (原始內容存檔於2023-08-03) (巴西葡萄牙語). 
  4. ^ Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Therapeutic Advances in Drug Safety (SAGE Publications). March 2018, 9 (3): 171–178. PMC 5810854 . PMID 29492246. doi:10.1177/2042098617750555. 

外部連結

編輯